Assessing the clinical relevance of oncogenic pathways in neoadjuvant breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages 1912-1915

  Verderio, Paolo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

BREAST CANCER; CLINICAL ASSESSMENT; EDITORIAL; GENE EXPRESSION; HUMAN; ONCOGENE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

BREAST NEOPLASMS; FEMALE; GENE REGULATORY NETWORKS; HUMANS;

EID: 84863919414     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.7386     Document Type: Editorial

References (45)

1. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002 (Pubitemid 34130608)
2. Creighton CJ, Hilger AM, Murthy S, et al: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66:3903-3911, 2006
3. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006 (Pubitemid 43264710)
4. Teschendorff AE, Miremadi A, Pinder SE, et al: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8:R157, 2007
5. Saal LH, Johansson P, Holm K, et al: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104:7564-7569, 2007 (Pubitemid 47185946)
6. Creighton CJ, Casa A, Lazard Z, et al: Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26:4078-4085, 2008
7. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
8. Farmer P, Bonnefoi H, Anderle P, et al: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15:68-74, 2009
9. Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107:10208-10213, 2010
10. Hess KR, Anderson K, Symmans WF, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244, 2006 (Pubitemid 46630780)
11. Tabchy A, Valero V, Vidaurre T, et al: Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16:5351-5361, 2010
12. Iwamoto T, Bianchini G, Booser D, et al: Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103:264-272, 2011
13. Desmedt C, Di Leo A, de Azambuja E, et al: Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 29:1578-1586, 2011
14. Bonnefoi H, Piccart M, Bogaerts J, et al: TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): A randomised phase 3 trial. Lancet Oncol 12:527-539, 2011
15. Hatzis C, Pusztai L, Valero V, et al: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305:1873-1881, 2011
16. Denkert C, Sinn BV, Issa Y, et al: Prediction of response to neoadjuvant chemotherapy: New biomarker approaches and concepts. Breast Care 6:265-272, 2011
17. Berruti A, Generali D, Kaufmann M, et al: International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 2011:147-151, 2011
18. Yeatman TJ: Predictive biomarkers: Identification and verification. J Clin Oncol 27:2743-2744, 2009
19. Sparano JA, Solin LJ: Defining the clinical utility of gene expression assays in breast cancer: The intersection of science and art in clinical decision making. J Clin Oncol 28:1625-1627, 2010
20. Shi L, Campbell G, Jones WD, et al: The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28:827-838, 2010
21. Luo J, Ellis MJ: Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer. Breast Cancer Res 12:112, 2010
22. Dupuy A, Simon RM: Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99:147-157, 2007
23. Ignatiadis M, Singhal SK, Desmedt C, et al: Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis. J Clin Oncol 30:1996-2004, 2012
24. Majumder PK, Febbo PG, Bikoff R, et al: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601, 2004
25. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357, 2006 (Pubitemid 43128862)
26. Carter SL, Eklund AC, Kohane IS, et al: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043-1048, 2006 (Pubitemid 44325930)
27. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
28. Wirapati P, Sotiriou C, Kunkel S, et al: Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65, 2008
29. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer, 2001, pp 16-26
30. Peduzzi P, Concato J, Kemper E, et al: A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49:1373-1379, 1996 (Pubitemid 27028925)
31. Robin X, Turck N, Hainard A, et al: pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77, 2011
32. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, 2008 (Pubitemid 351193639)
33. Dunkler D, Michiels S, Schemper M: Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43:745-751, 2007 (Pubitemid 46502906)
34. Key TJ, Appleby PN, Allen NE, et al: Pooling biomarker data from different studies of disease risk, with a focus on endogenous hormones. Cancer Epidemiol Biomarkers Prev 19:960-965, 2010
35. Bammler T, Beyer RP, Bhattacharya S, et al: Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2:351-356, 2005
36. Dobbin KK, Beer DG, Meyerson M, et al: Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 11:565-572, 2005 (Pubitemid 40116881)
37. Lusa L, McShane LM, Reid JF, et al: Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst 99:1715-1723, 2007 (Pubitemid 351767219)
38. Nelson PT, Wang WX, Wilfred BR, et al: Technical variables in highthroughput miRNA expression profiling: Much work remains to be done. Biochim Biophys Acta 1779:758-765, 2008
39. Taioli E, Bonassi S: Methodological issues in pooled analysis of biomarker studies. Mutation Research 512:85-92, 2002 (Pubitemid 35239958)
40. Luo J, Schumacher M, Scherer A, et al: A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J 10:278-291, 2010
41. Fuscoe JC, Tong W, Shi L: QA/QC issues to aid regulatory acceptance of microarray gene expression data. Environ Mol Mutagen 48:349-353, 2007 (Pubitemid 47011762)
42. MAQC Consortium, Shi L, Reid LH, et al: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24:1151-1161, 2006
43. Biganzoli E, Lama N, Ambrogi F, et al: Prediction of cancer outcome with microarrays. Lancet 365:1683, 2005
44. Kap M, Smedts F, Oosterhuis W, et al: Histological assessment of PAXgene tissue fixation and stabilization reagents. PLoS One 6:e27704, 2011
45. Günther K, Malentacchi F, Verderio P, et al: Implementation of a proficiency testing for the assessment of the preanalytical phase of blood samples used for RNA based analysis. Clin Chim Acta 413:779-786, 2012